We assessed the changes in sensitivity and specificity of creatine kinase (CK) isoenzymes at various times after acute myocardial infarction. CK-B was measured by an immunoinhibition technique. CK-MB was measured both by column chromatography on Sephadex DEAE A-50 and by electrophoresis on agarose gel. For CK-B, the sensitivity in detecting infarct varied from 11 % in the first 8 h after onset of symptoms to 80% at 32 h after the infarct. Patients having macro CK-BB exhibit anomalously high values for CK-B with respect to total CK. Patients having a mild infarct may show no increase in CK-isoenzymes.
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have reported sensitivity values for CK-B ranging from 86 to 100%. Our objectives were (a) to examine the temporal sensitivity and specificity of CK-B activity after AMI and (b) to compare the results by the immunochemical method with results obtained for the same samples by column chromatography and electrophoresis.
Materials and Methods

Patient Selection
A total of 74 patients suspected of having AMI, who were admitted to the coronary care unit of York Hospital between July 13 and Sept. 16, 1979 , were included in the study. These were not consecutive admissions, but no conscious bias was applied in their selection.
All patients were informed of the study and consented to be included. Of the 74 patients, 25 were women. One patient died and an autopsy verified the cause of death as AMI.
Department of Pathology, York Hospital, York, PA 17405. Received July 11, 1980; accepted Sept. 17, 1980. 1 The sensitivity of a test reflects its positivity in the presence of disease; specificity reflects its negativity in the absence of disease.
Specimen Collection and Handling
The study protocol specified collection of blood at 8-h intervals for a period of 72 h after admission to the hospital. Nine samples were collected from each of 63 patients. Six patients had eight samples each. Two patients had seven and five samples, respectively.
Two other patients were discharged after four samples had been collected, and one patient died before the third sample had been obtained.
No preservative was added to any sample of serum. Assays for creatine kinase (CK, CK-B, and CK-MB) were done within 24 h of specimen collection.
Clinical Diagnosis
The diagnosis of AMI was made by a panel of three cardiologists who were kept unaware of the CK-B and CK-MB values. Of the following three criteria at least two were required for the diagnosis: (a) a history of chest pain consistent with myocardial ischemia; (b), a value for total CK of twice the upper reference limit or more, or a characteristic increase of total CK to triple the initial value with a subsequent decrease; (c) electrocardiographic changes evolving over a period of up to 72 h, including the appearance of new Q-waves. In the absence of new Q-waves, but with typical pain and serum enzyme changes, alterations of the S-T segment or T-waves were taken to indicate intramural, in contrast to transmural, infarction.
By these criteria, 27 patients were classified in the AMI group and 47 in the non-AMI group. Column chromatography.
Assay Methods
Total
A modification of the method of Mercer (4) was used to separate CK-MB before its measurement.
Columns were prepared from DEAE-Sephadex A-50 in disposable 15-cm Pasteur pipets. The mini-columns 
Column chromatography.
We corrected the columnchromatographic data for the activity bias of the reagent used in the assay of eluates, to permit comparison of these results with those of the CK-B assay. Because the antibody inhibits only the M-subunit, the expected slope of a regression line relating CK-B and CK-MB activity is 0.5. The data in 
Sensitivity, Specificity, and Predictive Value
The data ( 
Quality Control
CK-B.
The between-run precision for CK-B was measured at two activity levels. The standard deviation at 140 U/L was ±9 U/L (n = 31) and at 277 U/L was ±14 U/L (n = 33).
Column chromatography. The between-run standard deviation for Ortho CPK Isoenzyme Control Serum (Lot 7S082) at 50 U/L was ±9 U/L (n = 28).
Elect rophoresis. The between-run standard deviation for Ortho CPK Isoenzyme Control Serum (Lot 7S082) at a CK-MB proportion of 15.9% was ±5.0% (n = 33).
Anomalous Results
Atypical
CK. One patient in our study showed anomalous results for CK-B and was excluded from the statistical analysis. By 
The Expected Range for CK-B
We estimated the expected range of values of CK-B in the absence of myocardial infarction from results for a group of 39 patients, none of whom had evidence of myocardial infarction by any of our criteria. However, they were all admitted to the critical care unit. A total of 332 samples was collected from these patients at 8-h intervals and assayed. The values ranged from ito 12 U/L, the highest value being observed in two patients.
These values are identical with those of Hofvendahl et al. (21) . The within-patient variation averaged 3.6 U/L (SD 2.4). 1-3, 8, 9, 23) are values that may be observed at any time between the onset of symptoms and three to five days later. Others (1,3) have emphasized the importance of proper timing of collection of serum samples if maximum information is to he obtained from enzyme measurements. Our results show very similar sensitivity and specificity values for CR-MB by electrophoresis or by column chromatography and for CR-B subunit activity during all time periods that we investigated.
Discussion
However, there are conditions under which the immunoinhibition procedure will yield false-positive results. Because CR-B subunit activity is being measured, any condition resulting in an increase in CR-BB activity in serum may be misinterpreted.
The "atypical" CK isoenzyme described by several investigators (9, (17) (18) (19) (20) will also appear as apparent CR-B or CR-MB activity in the immunoinhibition and column-chromatographic procedures, respectively. The incidence of the atypical creatine kinase in the population has been estimated by Sax (18) to be as high as 1 to 2%, but our experience in this study and in subsequent use of the test leads us to believe that the incidence is less than 1%. In our experience, the atypical creatine kinase presents as an impossibly high apparent CK-MB. When the CK-B activity exceeds 30% of the total CR, we expect to detect an atypical CR by electrophoresis.
One patient in our study presented with an admission CR of 223 U/L 8 h after onset of symptoms.
Her total lactate dehydrogenase and asparate aminotransferase values were within normal limits. Her CK-B subunit activity was 67 U/L (30% of total CK) and her CR-MB by column chromatography was 34 UIL. During the course of her stay, her total CK declined to 82 U/L but her CR-B and CK-MB activities remained nearly constant. Electrophoresis revealed the presence of the atypical CR isoenzyme with a mobility between that of CR-MM and CR-MB. Because of this and other experiences with atypical isoenzymes (25), we believe the activity of CR-B should not be multiplied by 2 as recommended by the manufacturer to give an apparent CR-MB activity, because in many cases, this will result in an apparent MB activity that exceeds the total CK activity! Clinically mild AMI continues to present a problem in laboratory diagnosis. Three of our patients who presented with typical chest pain and evolving electrocardiographic changes of intramural AMI showed no CR isoenzyme changes during the first three days after the onset of symptoms.
Subsequently where laboratory values vary during the course of the disease, the time at which the specimen is obtained may substantially influence the interpretation of the results of that test. In these situations, the temporal aspects of sensitivity, specificity, and predictive value must also be examined.
The sensitivity, specificity, and predictive value of CK-B and other measures of CK isoenzymes change after onset of AMI. The sensitivity for electrophoresis is slightly better than the other methods in the first 8 h after onset of symptoms. At later times, the information obtained by measurement of CR-B activity is equivalent to that obtained by measurement of CR-MB activity, except in cases in which an atypical CK isoenzyme is present. The times at which CR-B is measured should be predicated upon the onset of symptoms.
Samples obtained at admission (to establish a baseline value) and at the time of peak sensitivity for CK-B (8 to 15 h after onset of symptoms)
are the most informative in the diagnosis of AM!. Practically, these samples should be collected at 12 and 24 h after onset, to include peak values (24). At times exceeding 32 h, CR-B becomes less sensitive.
In mild or slowly evolving AM!, neither CK-B nor any other measure of CK isoenzymes may detect the evolving infarct.
In summary, the immunochemical method for measuring CR-B is faster than chromatography and more quantitative than electrophoresis.
It may be substituted for either as a part of the laboratory diagnosis of AMI. 
